Michael Wang, MD @michaelwangmd Twitter profile

Last Seen Profiles

@mxwntwnrw

@ethernal_tech

@kikuchimitsuru

@tinyruin

@nkgLD1QHJAo3L55

@raymopon

@CancerCenterAms

@FallenAcornBrew

@jpoganik

@Interna58832849

@35PAIS

@crot_ayo

@BoonKaboom

@nekona_baby

@YjgHhff8766

@TM_S69

@Redhead4645

@BKruchio

@gnoteaparty

@Valenci92782410

@EntoSamm

@Amayita50656663

@conpas_concon

@imprettyink

@AlmdnLbyb

@flawstear

@senseofesg

@mancsbound

@blackjack_asahi

@KonaseemaNTRFC

@ZoomerHistorian

@mowgli_meister

@ngoadvisor

@genki_saikyo_

@TomCottonAR

@penikmatt_ibu

Michael Wang, MD

@michaelwangmd

2 years

With my daughter, Dr. Jacky Wang, at ASH. I hope she becomes a lymphoma doctor!

23

11

612

Michael Wang, MD

@michaelwangmd

5 years

Today I was notified that my NIH RO1 grant got a score of 1%. I am so excited!

22

5

425

Michael Wang, MD

@michaelwangmd

5 years

My 82 yo mother was stranded in the storm in a flooded car this pm. A kind Spanish speaking couple invited her to their car and took her to their home. I drove 5 hours in rain through high waters and got her. I thanked the couple. They are my heroes today!

14

16

397

Michael Wang, MD

@michaelwangmd

4 years

In a world pandemic, with nonstop bad news, a little but beautiful flower of cell therapy for MCL blossomed quietly! Even on April Fools’ day, this is no joke! This is a most exciting milestone for relapsed #mantlecelllymphoma . This is unprecedented great news for our patients!

23

91

327

Michael Wang, MD

@michaelwangmd

5 years

Today I was notified by the Chief Academic Officer that I have been appointed to be the Puddin Clarke Endowed Professor as of December 1, 2019. I feel much appreciated and extremely honored by my beloved MD Anderson institution!

42

7

234

Michael Wang, MD

@michaelwangmd

4 years

Last weekend I was invited to a party by a good friend. When I got there, I saw 30 people eating next to each other around tables in the backyard, no masks. They told me all tested negative for COVID. I smiled and left. Cannot put my patients and family at risk.

12

5

213

Michael Wang, MD

@michaelwangmd

2 years

Thirty four years ago today I came to America. It has been quite a dream.

26

3

199

Michael Wang, MD

@michaelwangmd

4 years

Congratulations to all patients and their families affected by mantle cell lymphoma! This is a milestone progress! U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma | Gilead Sciences

14

44

181

Michael Wang, MD

@michaelwangmd

1 year

My patient from Alaska in remission after chemo free therapy for MCL!

9

7

170

Michael Wang, MD

@michaelwangmd

5 years

My wife sent this photo to me from Africa, I wish I was there!

8

3

146

Michael Wang, MD

@michaelwangmd

2 years

Today I am pacing the quiet floors of MD Anderson, rounding on our patients.

5

4

140

Michael Wang, MD

@michaelwangmd

5 years

Today I got a certificate for having served for 20 years at MD Anderson. It has been quite a unique journey!

22

0

135

Michael Wang, MD

@michaelwangmd

2 years

To all patients and families affected by #mantlecelllymphoma , we now have another magic bullet to treat MCL, this is wonderful news for you, congratulations! Many of you together with a big international team worked on this trial, it is a great team effort!

MD Anderson Cancer Center

@MDAndersonNews

2 years

“Oral pirtobrutinib could be used even after failure of prior BTK inhibitors and will benefit mantle cell lymphoma patients tremendously,” Wang says. “This is a milestone achievement in mantle cell lymphoma therapy.” @MichaelWangMD #EndCancer [2/2]

0

7

33

11

16

129

Michael Wang, MD

@michaelwangmd

3 years

Today, I got a punching bag, it has “MCL” on it, I could now exercise in my office!

13

6

117

Michael Wang, MD

@michaelwangmd

3 years

On my way to ASH with my wonderful colleague, Dr. Jason Westin!

2

1

113

Michael Wang, MD

@michaelwangmd

4 years

Rounding in the #MDAnderson hospital today to care for #lymphoma patients. See the quiet presence of the hospital, the empty Holcombe Boulevard, the silent corridor and myself before putting on full gear of protection. You all stay hone and enjoy!

13

6

112

Michael Wang, MD

@michaelwangmd

4 years

I have just finished presenting our exciting data with Loxo-305 in mantle cell lymphoma, Waldenstrom's Macroglobulinemia, Follicular lymphoma, marginal zone lymphoma, and large cell lymphoma. 2/2 patients post Car T cell mantle cell lymphoma responded to Loxo-305!!

3

8

106

Michael Wang, MD

@michaelwangmd

2 years

This New Year’s day I biked for 54 miles, which is my personal longest distance. May 2023 bring you health and joy!

11

2

107

Michael Wang, MD

@michaelwangmd

1 year

CAR T cell therapy is saving many lives from lymphoma, but is takes 2-4 weeks to manufacture. In the article I reviewed the technologies that could produce CAR T cells in 1-3 days. It is really exciting!

Cancer Discovery

@CD_AACR

1 year

In the Spotlight: Express delivery of next-generation #CARTcells with preserved naïve and stemness phenotypes for the treatment of aggressive #lymphomas , by @michaelwangmd . @MDAndersonNews

0

5

18

1

27

102

Michael Wang, MD

@michaelwangmd

2 years

ASH 2022 Thought 4 - The best work presented at ASH was almost never done by a single center. Multi-group complementary collaborations are needed for breakthrough research, quality and speed of progress. This is the open secret to win competition.

1

16

102

Michael Wang, MD

@michaelwangmd

4 years

Quiet indoor park in the MD Anderson hospital.

2

5

97

Michael Wang, MD

@michaelwangmd

3 years

Hot from press! In the inaugural issue of New England Journal of Medicine Evidence, our trial included patients who had received 4 drug/cell therapies & were given Zilovertamab vedotin which targeted ROR1. The ORR is 47% in MCL patients! via @NEJMEvidence

5

11

94

Michael Wang, MD

@michaelwangmd

4 years

I’m scheduled to receive the #COVIDVaccine on Thursday!

7

1

91

Michael Wang, MD

@michaelwangmd

4 years

So proud of my daughter, Jacqueline Wang, a current fourth year medical student, for contributing to this awesome podcast!

Jacqueline Wang

@jacky48

4 years

So excited to now officially be a part of this amazing team!

1

3

27

6

2

89

Michael Wang, MD

@michaelwangmd

4 years

Today, I am so excited that I visited my own lab for the first time after 6 months! All my lab members are in good health and great spirits. They are working hard. They said they missed me and I actually believe them!

3

1

87

Michael Wang, MD

@michaelwangmd

6 years

One of the many reasons I tweet is for our patients and their families to know that while their daily activities continue, many people like meyself are working hard every day including some nights and weekends trying to make solid progress in lymphoma.

8

86

Michael Wang, MD

@michaelwangmd

4 years

Many of my patients have not seen me or my team for two months. We keep in touch by telephone or emails. I am posting a photo at their request. I wish you all a relaxing weekend!

5

2

87

Michael Wang, MD

@michaelwangmd

5 years

While other kids play hard during their childhood years, I spent all my spare time carrying mom on my bike to and back from the hospital. I wanted to be a real doctor, the one who could decease or eliminate suffering. This has become my life and I have no regrets!

7

2

84

Michael Wang, MD

@michaelwangmd

3 years

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial - The Lancet Oncology. We dedicate this work to all the MCL patients and their families!

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with...

Induction with ibrutinib–rituximab in the frontline treatment of young patients with mantle cell lymphoma is active and safe. This approach allowed minimisation of the number of chemotherapy cycles,...

www.thelancet.com

5

20

86

Michael Wang, MD

@michaelwangmd

4 years

I am very excited, I am in the hurricane Laura ride-our team and will get to stay in the MD Anderson hospital for the night. It has been years since I slept in a on-call room!

16

2

82

Michael Wang, MD

@michaelwangmd

5 years

This is a major milestone of progress in cellular therapy in lymphoma! And it was initiated in the MD Anderson Lymphoma Moonshot Project. I am so glad to be a co- author.

Fehniger Lab

@LabFehniger

5 years

Cord-blood derived CD19-CAR modified NK cells induce remissions in B cell malignancies. February 6, 2020 issue of NEJM in print. Congrats to Katy Rezvani and the whole group! Stay tuned for online issue. NK cell immunotherapy works without CRS or ICANS! @NEJM #NKcell

5

109

238

4

21

81

Michael Wang, MD

@michaelwangmd

1 year

With my colleague the outstanding Dr. Jason Westin @ the American Society of Clinical Oncology in about an hour Jason is presenting the exciting data in ZUMA 7 phase 3 trial, before that we are presenting our posters!

3

82

Michael Wang, MD

@michaelwangmd

3 months

Congratulations to our patients with mantle cell lymphoma, we now have a second CAR T cell therapy! Our team led this multicenter clinical trial.

7

14

82

Michael Wang, MD

@michaelwangmd

3 years

Recently we have seen the emergence of CAR T cell treatment resistance in #mantlecelllymphoma , in order to meet this head on and overcome it, we are activating many trials at #MDAnderson . These trials represent the most cutting-edge therapeutics I have ever seen!

12

5

82

Michael Wang, MD

@michaelwangmd

2 years

This morning at ASH conference, I am getting ready to deliver a presentation on: Increasing Therapeutic Options in Mantle Cell Lymphoma!

6

3

78

Michael Wang, MD

@michaelwangmd

3 years

It has been a great year for #mantlecelllymphoma therapy. The usage of CAR T cells have been widespread. Data for pirtobrutinib and zilovertamab vendotin has matured. And bispecifics and immunotoxins are rapidly emerging!

3

6

78

Michael Wang, MD

@michaelwangmd

5 years

There are many ways to run a successful and productive laboratory. I really like what Dr. DeBaun does!

1

31

77

Michael Wang, MD

@michaelwangmd

2 years

Excited to share our latest paper online today on patients with mantle cell lymphoma. First paper on CAR T resistance mechanism in MCL patients using single cell. Checkpoint molecule TIGIT outstands. Congrats to @lamLinghua @Vivianjiang77 @DapengHao @MDAndersonNews

6

10

77

Michael Wang, MD

@michaelwangmd

6 years

In order to conduct Car T cell therapy safely, many teams need to work together in an organized fashion. These teams include Hematology/Oncology, a close family member, nursing, neurology, infectious disease, ICU, cardiology pharmacy, night call team, radiology and trial PI.

4

15

76

Michael Wang, MD

@michaelwangmd

3 months

TP53 mutation is a negative prognostic factor for patients with mantle cell lymphoma. In my presentation one hour ago, the combination of ibrutinib and Venetoclax produced a progression failure survival of 21 months and an overall survival of 47 months, impressive data!

6

11

77

Michael Wang, MD

@michaelwangmd

3 months

30 minutes ago in the late- breaker plenary session, I presented the data from ECHO trial from 195 hospitals across 26 countries. It is a new standard therapy. Congratulations to our patients with #mantlecelllymphoma !

9

77

Michael Wang, MD

@michaelwangmd

5 years

Window 2 trial is for newly-diagnosed patients with #mantlecelllymphoma . It is a Moonshot project trying to use chemo-free targeted therapies rituximab-ibrutinib-venetoclax to reduce chemotherapy. Congratulations to Richard for being the first patient in this historic trial!

Richard Bagdonas #fitfab

@richardbagdonas

5 years

Happy to announce I am patient #1 for the Window 2 trial! Thank you @michaelwangmd (pictured)

9

0

26

7

8

76

Michael Wang, MD

@michaelwangmd

2 years

Our CAR T cell therapy trial continues to have long median PFS and overall survival data after 3-year follow up time.

Journal of Clinical Oncology

@JCO_ASCO

2 years

🗣️ ZUMA-2 Study: 3-year follow-up of brexucabtagene autoleucel (KTE-X19) in patients with relapsed/refractory #MantleCellLymphoma 🙌 91% objective response 👍 PFS 25.8 months Read in #JCO : #lymsm @michaelwangmd

0

16

59

1

17

75

Michael Wang, MD

@michaelwangmd

2 years

I am sitting in a plane in a good mood going somewhere to celebrate the FDA approval for pirtobrutinib for relapsed #mantlecelllymphoma !

5

0

73

Michael Wang, MD

@michaelwangmd

2 years

Today for the first time I visited the headquarter of the Leukemia & Lymphoma Society in person. I joined a distinguished panel of academic clinicians and scientists to discuss research priorities on #mantlecelllymphoma . It was a blast!

2

5

74

Michael Wang, MD

@michaelwangmd

5 months

Had a great time discussing science, medicine and life with my colleagues Drs. @chrisflowers and @jasonwestin . Naples is beautiful city!

7

1

74

Michael Wang, MD

@michaelwangmd

2 years

This year there are very significant advances in the treatment #mantlecelllymphoma at the American Society of Hematology annual meeting. I cannot wait to attend, it is next week!

10

5

73

Michael Wang, MD

@michaelwangmd

2 years

Today my heart is with our patients and their families. Your wisdom and your unshakable spirit constantly inspire us. May you have a joyous Thanksgiving!

2

4

70

Michael Wang, MD

@michaelwangmd

3 years

Friendship and brotherhood!

5

0

73

Michael Wang, MD

@michaelwangmd

9 months

It was such an exciting time presenting our data on SYMPATICO trial. It is a milestone achievement for our patients with mantle cell lymphoma in the world!

1

6

72

Michael Wang, MD

@michaelwangmd

2 years

This is a milestone advance in MCL! A 6.7 year progresses free survival is a new benchmark for older patients!

MD Anderson Cancer Center

@MDAndersonNews

2 years

#ASCO22 LBA502: The Phase III SHINE clinical trial led by Dr. Michael Wang found that ibrutinib plus bendamustine-rituximab improved progression-free survival in mantle cell lymphoma patients over age 65: @MichaelWangMD #EndCancer

0

13

30

4

12

72

Michael Wang, MD

@michaelwangmd

6 years

First day in the clinic in 2019. Gave good news to many patients this morning, exciting! We are working to open more Car T cell trials. We are enrolling patients on a reversible BTK inhibitor. 2019 is full of promises!

2

11

69

Michael Wang, MD

@michaelwangmd

5 years

Ibrutinib is a wonderful drug, it has revolutionized therapy for many B cell malignancies. Severe toxicities are rare but 2 things we should never do. Never take it with long-term steroids, severe infections might occur. Never take it with warfarin, severe bleedings might happen.

1

9

68

Michael Wang, MD

@michaelwangmd

1 year

We have just opened a trispecific antibody trial for relapsed #mantlecelllymphoma . It is promising!

4

6

69

Michael Wang, MD

@michaelwangmd

1 year

Lugano is beautiful.

3

69

Michael Wang, MD

@michaelwangmd

3 years

As we celebrate a great year of progress in the science, technology and medicine for #mantlecelllymphoma , and bid farewell to 2021. Let’s welcome another year of rapid advances for our patients and their families! 2022 is full of promises!

13

3

69

Michael Wang, MD

@michaelwangmd

2 years

Biked for 40 miles today, not too bad.

5

1

68

Michael Wang, MD

@michaelwangmd

3 years

Wishing you a great pre Christmas weekend!

6

1

67

Michael Wang, MD

@michaelwangmd

3 years

This study from the Wang Lab published in Nature Communications using single cell RNA seq highlights the diverse and dynamic tumor and immune programs underlying therapy resistance in MCL. We thank all who continue to support our MCL research!

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in...

Nature Communications - Mantle cell lymphoma can be refractory to treatment. Here, the authors used single cell sequencing to study the tumours of patients that were responsive and resistant to...

www.nature.com

3

17

69

Michael Wang, MD

@michaelwangmd

2 years

On duty at the MD Anderson booth ( #6122 ), please visit us, and talk with me, it is free!

3

2

68

Michael Wang, MD

@michaelwangmd

3 months

An international randomized phase 3 trial is a huge undertaking, hundreds of millions from an industry sponsor, tremendous efforts from patients and families, hard work from often hundreds of international hospitals, with government approval, credits go to all hidden heroes!

5

11

69

Michael Wang, MD

@michaelwangmd

6 months

Today we had a meeting on clinical trial operations on #mantlecelllymphoma at MD Anderson. We are expanding our portfolio to continue to include all the best cutting edge therapies for our patients!

4

2

67

Michael Wang, MD

@michaelwangmd

4 years

Just got the COVID-19 vaccine, feeling well. No local site irritation, no symptoms so far for 30 minutes.

0

2

67

Michael Wang, MD

@michaelwangmd

2 years

It is Spring, enjoy the beautiful outdoors!

2

1

66

Michael Wang, MD

@michaelwangmd

3 years

I will be presenting exciting updates on pirtobrutinib, a reversible BTK inhibitor and zilovertamab vedotin, a ROR1 antibody MMAE toxin conjugate in relapsed #mantlecelllymphoma at ASH 2021, stay tuned!

2

3

67

Michael Wang, MD

@michaelwangmd

7 months

Recently, our laboratory reported that pirtobrutinib & venetoclax combination overcomes resistance to targeted & chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma ( #MCL ), activating enrollment for a phase II clinical trial.

4

8

64

Michael Wang, MD

@michaelwangmd

4 years

When I got the news that FDA approved Tecartus for mantle cell lymphoma on 7-24-2020 I was driving my family to Mississippi on Highway I-10 in heavy rain. I was so excited that my wife asked for an immediate driver switch!

2

4

63

Michael Wang, MD

@michaelwangmd

5 years

My father came from rural China, he survived poverty/starvation but refused to quit school. He became an engineer. During my childhood, he told me stories, flew kites and played basketball with me. He taught me mathematics and physics. Happy Father’s Day, Baba! I love you!

2

0

63

Michael Wang, MD

@michaelwangmd

5 years

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management - Jain - 2019 - American Journal of Hematology - Wiley Online Library

2

20

63

Michael Wang, MD

@michaelwangmd

5 years

Today I am thrilled to report that we are opening a cohort for relapsed refractory #mantlecelllymphoma with antiCD19 Car T cells in a clinical trial.

3

9

64

Michael Wang, MD

@michaelwangmd

2 years

I am looking forward to sharing this data with all. This is an international trial that included over 520 MCL patients, more than 180 best hospitals in the world in 30 some countries. It took 10 years!

Chan Cheah

@chanyooncheah

2 years

@michaelwangmd to present primary outcome analysis from the SHINE study of BR +/- ibrutinib in 1L transplant ineligible mantle cell lymphoma #ASCO22 ... been waiting for a long time for these results. V interested in the data.

1

3

19

4

5

64

Michael Wang, MD

@michaelwangmd

3 months

ASCO, American Society of Clinical Oncology is the largest oncology event in the world. I am looking forward to present new data on #mantlecelllymphoma !

2

5

63

Michael Wang, MD

@michaelwangmd

2 years

Academic scholars in lymphoma and CLL, lymphominiacs!

4

1

62

Michael Wang, MD

@michaelwangmd

3 years

Came back from ASH conference last night, rounded in the hospital, a bit overwhelmed, on my way home, I ran into a family member who said:” God bless you, Dr. Wang”. I am so touched!

5

0

60

Michael Wang, MD

@michaelwangmd

4 years

A great honor for me to lead Lymphoma portion of this trial. It is rare that a first-in-human phase 1 trial could be published in a high impact journal such as Lancet. It is another breakthrough attesting our unprecedented time, a time of accelerated science/biotech translation!

Vivek Subbiah, MD

@VivekSubbiah

4 years

Friday morning motivation 👉🏼Fantastic waterfall plots 👉🏼 Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study @OncoAlert

0

5

18

2

4

62

Michael Wang, MD

@michaelwangmd

5 years

I am forever grateful to my mentor Dr. Jorge Romaguera. He is a pioneer in #mantlecelllymphoma clinical research and a master clinician!

Maria Badillo, MSN RN OCN CCRP

@jaymbsanycgmai1

5 years

Retirement party of our dear Dr. Jorge Romaguera. We will truly miss him as our teacher, mentor and advisor. He is a good man inside and out. @MDAndersonNews @michaelwangmd

1

2

20

2

5

60

Michael Wang, MD

@michaelwangmd

3 years

Enjoy this beautiful autumn, have a great weekend!

3

0

60

Michael Wang, MD

@michaelwangmd

3 years

After two years of virtual ASH, I am very excited that I get to go in person this year! Will witness exciting advances and will see friends!

4

0

58

Michael Wang, MD

@michaelwangmd

2 years

Under the support and collaboration of Dr. Tender and colleagues in Janssen Oncology, we designed the SHINE MCL trial 10 years ago. On behalf of all colleagues, I shall present this important trial tomorrow at ASCO!

Mark Wildgust (he/him)

@MAWildgust

2 years

And now here Craig Tendler head of Janssen Oncology Late Stage R&D.

0

13

1

2

58

Michael Wang, MD

@michaelwangmd

6 years

CAR T cell therapy is a major advance in malignant Hematology and has been approved for ALL and large cell lymphoma. I believe 2019 will be a great year for our patients with relapsed mantle cell lymphoma. Our group is leading an international registration trial.

7

12

58

Michael Wang, MD

@michaelwangmd

4 years

I have just got the second dose of COVID-19 vaccine. I believe all will receive it soon. Science prevails!

2

4

59

Michael Wang, MD

@michaelwangmd

2 years

Wishing you a relaxing weekend!

2

0

58

Michael Wang, MD

@michaelwangmd

4 years

I found a poem written in 1998 when I was a little unhappy. I worked in National Institute of Health located on the Rockville Pike. I rode M-14 to Ann Arbor during a harsh internship. And I traveled Fred Hatchingdon PKway to Norwalk Hospital for residency, then came to Houston.

7

1

59

Michael Wang, MD

@michaelwangmd

3 years

With Dr. Barbara Pro from Northwest University Chicago. Dr. Pro is an intentionally known expert in lymphoma therapy. She was on the MD Andersen faculty for many years!

1

57

Michael Wang, MD

@michaelwangmd

2 years

Happy holidays to all my patients and families!

7

1

58

Michael Wang, MD

@michaelwangmd

2 years

So happy to exchange lymphoma research ideas with the best in the field. Dr. Laurie Sehn @ Sehnlaurie, Judith Trotman ⁦ @JudithTrotman1 ⁩ and @Gillessallies

3

1

59

Michael Wang, MD

@michaelwangmd

4 years

Albert Einstein once described his three rules of work: (1) Out of clutter find simplicity. (2) From discord find harmony. (3) In the middle of difficulty lies opportunity. We might need to refer to these at such difficult times.

2

9

54

Michael Wang, MD

@michaelwangmd

2 years

Have a great weekend, nature is smiling at us!

7

1

53

Michael Wang, MD

@michaelwangmd

2 years

ASH 2022 Thought 12 - We are curing hematology malignancies. As for me, I will continue to work hard with my patients, their families, with industry colleagues and academic collaborators to accelerate the cure of Mantle Cell Lymphoma. We are within striking distance!

2

3

55

Michael Wang, MD

@michaelwangmd

4 years

Many patients get online often to search for information on lymphoma and they frequently complain that they are discouraged by what they find. Please keep in mind the web has lots of outdated information! I advise all to listen to your lymphoma doctors not to the WWW!

7

5

54

Michael Wang, MD

@michaelwangmd

5 years

Day 3 hospital rounding during Thanksgiving Holiday in the #Mdanderson hospital, with my good friend and colleague Dr. Nathan Fowler.

3

1

54

Michael Wang, MD

@michaelwangmd

3 months

ASCO has been blast! Much data on mantle cell lymphoma was presented. See you, Chicago the same time next year!

4

1

56

Michael Wang, MD

@michaelwangmd

3 years

Wishing you a fantastic Thanksgiving!

6

1

57

Michael Wang, MD

@michaelwangmd

3 years

This morning I presented:”Best therapies in TP53 mutated mantle cell lymphoma” in the pan-pacific Lymphoma Conference. It is a true honor to be in a distinguished panel of faculty! Hawaii is beautiful!

5

1

54

Michael Wang, MD

@michaelwangmd

9 months

Day 1 at the American Hematology Society Annual Conference. Will present a summary of all 4 generations of BTK inhibitors. So excited to be on a distinguished panel of speakers!

1

2

57

Michael Wang, MD

@michaelwangmd

4 years

With full PPE, many of patients could not recognize me, however, when I start to talk, they smile after hearing my voice.

1

0

54

Michael Wang, MD

@michaelwangmd

4 years

Today I rounded in the hospital and saw many patients with lymphoma. I thank all who send their wishes for me to take good care of the patients and myself!

3

0

55

Michael Wang, MD

@michaelwangmd

4 years

Due to COVID-19 many of my patients are being treated at home, I hope you take care, keep in touch and stay virus- free. In case of emergencies or trouble connecting with us, email at miwang @mdanderson .org or text or call my cell 713-320-5264, I miss you all!